PSMA-UCAR T (BRL-302)
Phase 1Biologic
PSMA-UCAR T (BRL-302) is one of 49 biologic programs targeting Metastatic Prostate Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Metastatic Prostate Cancer
#DrugCompanyPhaseTrials
1Casodex
IIstituto Clinico Humanitas
Approved
Xtandi
AstellasPhase 3
Zytiga
Johnson & JohnsonPhase 3
Firmagon
FerringApproved
Taxotere
AAvyxa
Phase 3
Balversa
Johnson & JohnsonApproved
Zoladex
TTerSera Therapeutics LLC
Approved
Erleada
Johnson & JohnsonPhase 3
Nubeqa
BayerPhase 3
Jevtana
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PSMA-UCAR T (BRL-302). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SShanghai Changzheng Hospital